Perigon Wealth Management’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$768K Buy
2,071
+203
+11% +$71.7K 0.01% 695
2026
Q2
$671K Buy
1,868
+286
+18% +$87.4K 0.01% 747
2026
Q1
$397K Sell
1,582
-449
-22% -$112K 0.01% 907
2025
Q4
$559K Buy
2,031
+423
+26% +$116K 0.01% 741
2025
Q3
$422K Buy
1,608
+422
+36% +$103K 0.01% 811
2025
Q2
$259K Sell
1,186
-497
-30% -$106K 0.01% 897
2025
Q1
$377K Sell
1,683
-25
-1% -$6.89K 0.01% 729
2024
Q4
$576K Sell
1,708
-42
-2% -$13.2K 0.01% 595
2024
Q3
$525K Buy
+1,750
New +$536K 0.01% 606
2024
Q1
– Sell
-1,863
Closed -$656K – 926
2023
Q4
$656K Sell
1,863
-15
-0.8% -$5.31K 0.02% 431
2023
Q3
$705K Sell
1,878
-20
-1% -$7.73K 0.03% 375
2023
Q2
$726K Buy
1,898
+23
+1% +$8.22K 0.03% 372
2023
Q1
$650K Buy
1,875
+48
+3% +$14K 0.04% 346
2022
Q4
$430K Buy
+1,827
New +$433K 0.03% 419
2022
Q2
– Sell
-668
Closed -$274K – 628
2022
Q1
$274K Buy
668
+156
+30% +$61.1K 0.02% 489
2021
Q4
$240K Buy
+512
New +$220K 0.02% 510
2021
Q1
– Sell
-95
Closed -$27K – 1041
2020
Q4
$27K Buy
+95
New +$26.7K ﹤0.01% 943

Other funds holding WST

Perigon Wealth Management's WST Position: Q3 2026 in Review

Perigon Wealth Management increased its West Pharmaceutical (WST) stake by 11% in Q3 2026, buying an estimated $71.7K and bringing the position to 2,071 shares worth $768K. The position accounts for 0.01% of the portfolio, ranked #695.

Perigon Wealth Management first reported a position in WST in Q4 2020 and has held it in 17 quarters since. 189 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • Perigon Wealth Management held 2,071 shares of West Pharmaceutical worth $768K as of Q3 2026.
  • Perigon Wealth Management bought 203 West Pharmaceutical shares in Q3 2026, an estimated $71.7K.
  • West Pharmaceutical made up 0.01% of Perigon Wealth Management's portfolio in Q3 2026, its #695 holding.
  • Perigon Wealth Management first reported a position in West Pharmaceutical in Q4 2020 and has held it in 17 quarters since.
  • 189 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Perigon Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.